Search Results for "hATTR"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
HELIOS-A: Efficacy and safety of vutrisiran in patients with hATTR with polyneuropathy
Summary of the efficacy and safety results of vutrisiran compared to external placebo for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy, as published in the journal Amyloid, 2022.
Summary of the efficacy and safety results of vutrisiran compared to external placebo for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy, as published in the journal Amyloid, 2022.
